How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

799 results for

Galantamine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Stopping Donepezil may be linked to nursing home placement for people with Alzheimer’s disease, but a “cause and effect” not conclusive

the four year study period. The participants in each group had similar characteristics and stage of disease at the beginning of the trial, but we don’t know what medication they took in the last three years of the study. The authors considered that the overall trial design was representative of usual care. What does current guidance say on this issue? NICE 2011 guidance recommends donepezil (or one of the related acetyl cholinesterase inhibitors, galantamine or rivastigmine) as a medical option (...) characteristics and stage of disease at the beginning of the trial, but we don’t know what medication they took in the last three years of the study. The authors considered that the overall trial design was representative of usual care. What does current guidance say on this issue? NICE 2011 guidance recommends donepezil (or one of the related acetyl cholinesterase inhibitors, galantamine or rivastigmine) as a medical option to treat cognitive symptoms of mild to moderate Alzheimer’s disease, provided

2018 NIHR Dissemination Centre

144. Pharmacological interventions for cognitive decline in people with Down syndrome. (PubMed)

Pharmacological interventions for cognitive decline in people with Down syndrome. People with Down syndrome are vulnerable to developing dementia at an earlier age than the general population. Alzheimer's disease and cognitive decline in people with Down syndrome can place a significant burden on both the person with Down syndrome and their family and carers. Various pharmacological interventions, including donepezil, galantamine, memantine and rivastigmine, appear to have some effect

Full Text available with Trip Pro

2015 Cochrane

145. Recommendations on screening for cognitive impairment in older adults

important change. The MMSE and the MoCA tools are commonly used by Canadian clinicians in clinical practice. 14 Treatments include medications such as cho- linesterase inhibitors (i.e., donepezil, rivastigmine and galantamine), dietary supplements and vita- mins, and nonpharmacologic interventions such as exercise, and cognitive training and rehabili- tation. 10 Provincial payment for the medications used in primary care practice is often linked to cognitive assessment scores measured by the screening (...) interventions approved for use in Canada (e.g., cholinesterase inhibitors, such as donepezil, rivastigmine and galantamine), dietary supplements or vitamins and nonpharmacologic interventions (e.g., exer- cise, cognitive training and rehabilitation). The task force workgroup decided to treat the key question regarding the accuracy of screening tools (key question 6 in Appendix 2) as a contex- tual question. This was because there were no trials of screening programs and there was evi- dence that treatment

2015 CPG Infobase

146. Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials. (PubMed)

patients at 119 sites; study 2: n = 858 at 158 sites; and study 3: n = 734 at 126 sites). The 24-week studies were conducted from October 2013 to January 2017; final follow-up on January 12, 2017.Idalopirdine (10, 30, or 60 mg/d) or placebo added to cholinesterase inhibitor treatment (donepezil in studies 1 and 2; donepezil, rivastigmine, or galantamine in study 3).Primary end point in all 3 studies: change in cognition total score (range, 0-70; a lower score indicates less impairment) from baseline

Full Text available with Trip Pro

2018 JAMA

147. SNMMI Procedure Standard/EANM Practice Guideline for Amyloid PET Imaging of the Brain 1.0

orbreasttissue.However,forcautioninthisrareinstanceandbecause of the potential for radiotracer excretion in human milk and potential radiation exposure to infants, either avoid performing amyloid PET imaging on a breastfeeding mother or have the mother interrupt breastfeeding for 24 h after administration of the 18 F radiotracer. There is no known evidence to suggest that there are drug interactions between amyloid radiotracers and common drugs pre- scribed for dementia patients, such as donepezil, galantamine

2016 European Association of Nuclear Medicine

148. Drugs to avoid in 2015

of their disproportionate adverse effects and many interactions with other drugs. None of the available drugs has been shown to slow progression toward dependency, yet all carry a risk of life-threatening adverse effects and severe drug inter - actions (Prescrire Int n° 128 and Rev Prescrire n° 363, 364). It is better to focus on reorganising the patient’s daily life, keeping him or her active, and providing support and help for caring relatives. – Donepezil, galantamine and rivastigmine, three cholinesterase

2015 Prescrire

149. Inhibition of Human P-glycoprotein Transport and Substrate Binding Using a Galantamine Dimer (PubMed)

Inhibition of Human P-glycoprotein Transport and Substrate Binding Using a Galantamine Dimer The human multidrug resistance transporter P-glycoprotein (P-gp) prevents the entry of compounds into the brain by an active efflux mechanism at the blood-brain barrier (BBB). Treatment of neurodegenerative diseases, therefore, has become a challenge and the development of new reversible inhibitors of P-gp is pertinent to overcome this problem. We report the design and synthesis of a crosslinked agent (...) based on the Alzheimer's disease treatment galantamine (Gal-2) that inhibits P-gp-mediated efflux from cultured cells. Gal-2 was found to inhibit the efflux of the fluorescent P-gp substrate rhodamine 123 in cancer cells that over-express P-gp with an IC(50) value of approximately 0.6 microM. In addition, Gal-2 was found to inhibit the efflux of therapeutic substrates of P-gp, such as doxorubicin, daunomycin and verapamil with IC(50) values ranging from 0.3 to 1.6 microM. Through competition

Full Text available with Trip Pro

2009 Biochemical and biophysical research communications

150. Galantamine improves apomorphine-induced deficits in prepulse inhibition via muscarinic ACh receptors in mice (PubMed)

Galantamine improves apomorphine-induced deficits in prepulse inhibition via muscarinic ACh receptors in mice Galantamine, a weak acetylcholine esterase (AChE) inhibitor and allosteric potentiator of nicotinic ACh receptors (nAChRs), improves apomorphine-induced deficits in prepulse inhibition (PPI), sensory information-processing deficits, via a nAChR-independent mechanism. The present study examined the role of muscarinic ACh receptors (mAChRs) in the effect of galantamine, and studied (...) the mechanism of galantamine-induced increases in prefrontal ACh levels in mice.Apomorphine (1 mg kg(-1)) was administered to male ddY mice (9-10 weeks old) to create a PPI deficit model. Extracellular ACh concentrations in the prefrontal cortex were measured by in vivo microdialysis.Galantamine- and donepezil-mediated improvements in apomorphine-induced PPI deficits were blocked by the preferential M(1) mAChR antagonist telenzepine. The mAChR agonist oxotremorine also improved apomorphine-induced PPI

Full Text available with Trip Pro

2009 British journal of pharmacology

151. Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER)

Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER) Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01039194 Recruitment Status : Completed First Posted

2009 Clinical Trials

152. Characteristics of Treatment Responders to Galantamine

Characteristics of Treatment Responders to Galantamine Characteristics of Treatment Responders to Galantamine - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Characteristics of Treatment Responders (...) to Galantamine The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01029132 Recruitment Status : Completed First Posted : December 9, 2009 Last Update Posted : January 6, 2016 Sponsor: Samsung Medical Center Collaborator: Janssen Korea, Ltd., Korea Information provided by (Responsible Party): Doh Kwan Kim

2009 Clinical Trials

153. Analyses of mortality risk in patients with dementia treated with galantamine. (PubMed)

Analyses of mortality risk in patients with dementia treated with galantamine. To analyze mortality data from patients with Alzheimer's disease (AD), Alzheimer's plus cerebrovascular disease (AD + CVD) or vascular dementia (VaD).(1) Meta-analysis of mortality data from double-blind, placebo-controlled, randomized trials; and (2) recontact study to collect additional longer term mortality data from previous galantamine trial participants. RESULTS (META-ANALYSIS): Across 12 trials (< or =6 months (...) duration), there was no increased risk of mortality associated with the use of galantamine (n = 4116) compared with that of placebo (n = 2386) (OR galantamine/placebo: 0.67, 95% CI 0.41-1.10). RESULTS (RECONTACT STUDY): Median survival was 79 months for patients with AD (n = 478) and 59 months for patients with AD + CVD (n = 180) or VaD (n = 145). Prolonged galantamine treatment (> vs < or =6 months) was not associated with decreased survival time (75 vs 61 months respectively; P = 0.02). Cox

2009 Acta neurologica Scandinavica

154. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial. (PubMed)

Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial. The efficacy of galantamine has been shown in patients with mild, moderate, and advanced moderate Alzheimer's disease (AD). Here we report its efficacy in patients with severe AD.Between December, 2003, and March, 2007, patients aged 84 (SD 6) years with severe AD (mini-mental state examination [MMSE] score 5-12 points), in a nursing home setting (...) were randomly assigned to receive galantamine (n=207), titrated initially to 24 mg/day, or placebo (n=200). Co-primary efficacy measures for cognitive function and ability to undertake normal daily activities were the severe impairment battery (SIB) and the seven-item minimum data set-activities of daily living (MDS-ADL), respectively. Adverse events, vital signs, laboratory parameters, and electrocardiograms were monitored. This trial is registered with ClinicalTrials.gov, number NCT00216593.168

2009 Lancet Neurology

155. A double-blind comparison of galantamine hydrobromide ER and placebo in Parkinson disease. (PubMed)

A double-blind comparison of galantamine hydrobromide ER and placebo in Parkinson disease. To study the efficacy and safety of galantamine hydrobromide ER for the enhancement of cognition in non-demented Parkinson's patients (PD).Sixty-nine non-demented PD participants were randomised in a double-blind, placebo-controlled study of galantamine or placebo. Galantamine was administered over 16 weeks (8 mg/day for 4 weeks, a therapeutic dose of 16 mg/day for 6 weeks and a maximum dose of 24 mg/day (...) measures. Most common adverse events were gastrointestinal and self-reported worsening of PD symptoms.Contrary to our hypotheses, galantamine treatment did not improve attention/executive, memory or visuospatial performance in non-demented PD patients. Further, there was a high, statistically significant drop-out rate in the treatment group due to gastrointestinal side effects and self-reported worsening of PD symptoms. Treatment with galantamine did not enhance self-perception of mental sharpness

2009 Journal of neurology, neurosurgery, and psychiatry

156. The effects of galantamine on psychopathology in chronic stable schizophrenia. (PubMed)

The effects of galantamine on psychopathology in chronic stable schizophrenia. Galantamine is an acetylcholinesterase inhibitor and an allosteric modulator of the alpha4beta2 and alpha7 nicotinic receptors. There are several case reports describing the potential benefits of galantamine for negative symptoms associated with schizophrenia. This secondary analysis describes the effects of galantamine on psychopathology in people with schizophrenia.Subjects with clinically stable chronic (...) schizophrenia were randomized to adjunctive galantamine (24 mg/d) or placebo in a 12-week double-blind trial. Symptomatology was assessed with the Brief Psychiatric Rating Scale (BPRS) and the Clinical Global Impression Scale. The Scale for the Assessment of Negative Symptoms (SANS) was used to measure negative symptoms.Eighty-six patients with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition diagnosis of schizophrenia or schizoaffective disorder taking a stable dose of antipsychotic

Full Text available with Trip Pro

2009 Clinical neuropharmacology

157. [Galantamine (reminyl) in the treatment of severe Alzheimer's disease]. (PubMed)

[Galantamine (reminyl) in the treatment of severe Alzheimer's disease]. Twenty-five patients with Alzheimer's disease (AD) in moderate-severe and severe stages received galantamine in dosage 8 mg daily during the 1st month with the following increasing to 16 mg daily. Six patients received 24 mg per day from the 3rd month. The total duration of therapy was 26 weeks. 15 patients received in addition the antipsychotic therapy. Reminyl had a positive effect on cognitive functions and psychotic

2009 Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov [i] Vserossiiskoe obshchestvo psikhiatrov

158. Electroencephalographic effects of galantamine in major depressive disorder. (PubMed)

Electroencephalographic effects of galantamine in major depressive disorder. Nicotinic acetylcholine receptor stimulation is a potential target for controlling symptoms in several psychiatric disorders. Galantamine is a cholinesterase inhibitor that can modulate the nicotinic receptor sites. In this study, we examined the effect of galantamine on the quantitative EEG in patients with major depression. Twenty patients were included in a randomized, double-blinded, placebo-controlled trial (...) . Patients received galantamine (8 mg/day for 4 weeks then 16 mg/day for another 4 weeks) or placebo for eight weeks. Quantitative EEG using the international 10 to 20 configuration, 9 minutes of resting, eyes closed, and eyes open was done before and after the study period. Nineteen patients completed the study and their data were included in the final analysis. The results showed that galantamine compared with placebo reduced absolute band power that was statistically significant (using multivariate

2009 Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society

159. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. (PubMed)

Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. The study aim was to conduct a systematic review of the evidence from randomized, placebo controlled trials related to the efficacy of donepezil, rivastigmine and galantamine in the treatment of behavioral and psychological symptoms of Alzheimer's (...) disease.Electronic database searches of MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials were carried out using multiple search terms. Articles included were original publications of randomized, placebo-controlled trials of monotherapy of donepezil, rivastigmine or galantamine that reported a behavioral outcome measure.14 studies were identified that matched inclusion criteria. Nine were of donepezil, three of galantamine and two of rivastigmine. Median study treatment length was 24 weeks

2009 International psychogeriatrics / IPA

160. A double-blind, placebo-controlled pilot study of galantamine to improve cognitive dysfunction in minimally symptomatic bipolar disorder. (PubMed)

A double-blind, placebo-controlled pilot study of galantamine to improve cognitive dysfunction in minimally symptomatic bipolar disorder. There is increasing evidence that cognitive impairment is common in patients with bipolar disorder. The purpose of this study was to determine whether galantamine augmentation improved cognition in patients with euthymic bipolar disorder. In addition, the effect of galantamine on clinical measures of functioning and psychopathology was assessed.This study (...) was a randomized double-blind, placebo-controlled, parallel design examining the impact of galantamine augmentation on cognition and other clinical measures in 30 patients during the course of 3 months. Sixteen subjects who completed baseline and follow-up second neuropsychological testing were evaluable (10 with galantamine and 6 with placebo).The galantamine group showed improved performance on the California Verbal Learning Test total learning and the placebo group showed improved performance on the 2 Delis

2009 Journal of Clinical Psychopharmacology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>